Department of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine, Columbia, South Carolina, United States.
Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States.
Am J Physiol Cell Physiol. 2024 Feb 1;326(2):C606-C621. doi: 10.1152/ajpcell.00548.2023. Epub 2024 Jan 8.
Immune cell-driven pathways are linked to cancer cachexia. Tumor presence is associated with immune cell infiltration whereas cytotoxic chemotherapies reduce immune cell counts. Despite these paradoxical effects, both cancer and chemotherapy can cause cachexia; however, our understanding of immune responses in the cachexia condition with cancer and chemotherapy is largely unknown. We sought to advance our understanding of the immunology underlying cancer and cancer with chemotherapy-induced cachexia. CD2F1 mice were given 10 C26 cells, followed by five doses of 5-fluorouracil (5FU; 30 mg/kg LM, ip) or PBS. Indices of cachexia and tumor (TUM), skeletal muscle (SKM), and adipose tissue (AT) immune cell populations were examined using high-parameter flow cytometry. Although 5FU was able to stunt tumor growth, % body weight loss and muscle mass were not different between C26 and C26 + 5FU. C26 increased CD11bLy6g and CD11bLy6c inflammatory myeloid cells in SKM and AT; however, both populations were reduced with C26 + 5FU. tSNE analysis revealed 24 SKM macrophage subsets wherein 8 were changed with C26 or C26 + 5FU. C26 + 5FU increased SKM CD11bCD11c dendritic cells, CD11bNK1.1 NK-cells, and CD11bB220 B-cells, and reduced Ly6cCX3CR1CD206CD163CD11cMHCII infiltrated macrophages and other CD11bLy6c myeloid cells compared with C26. Both C26 and C26 + 5FU had elevated CD11bF480CD206MHCII or more specifically Ly6cCX3CR1CD206CD163CD11cMHCII profibrotic macrophages. 5FU suppressed tumor growth and decreased SKM and AT inflammatory immune cells without protecting against cachexia suggesting that these cells are not required for wasting. However, profibrotic cells and muscle inflammatory/atrophic signaling appear consistent with cancer- and cancer with chemotherapy-induced wasting and remain potential therapeutic targets. Despite being an immune-driven condition, our understanding of skeletal muscle and adipose tissue immune cells with cachexia is limited. Here, we identified immune cell populations in tumors, skeletal muscle, and adipose tissue in C26 tumor-bearing mice with/without 5-fluorouracil (5FU). C26 and C26 + 5FU had increased skeletal muscle profibrotic macrophages, but 5FU reduced inflammatory myeloid cells without sparing mass. Tumor presence and chemotherapy have contrasting effects on certain immune cells, which appeared not necessary for wasting.
免疫细胞驱动的途径与癌症恶病质有关。肿瘤的存在与免疫细胞浸润有关,而细胞毒性化疗则会减少免疫细胞数量。尽管存在这种矛盾的影响,但癌症和化疗都可能导致恶病质;然而,我们对癌症和化疗引起的恶病质条件下的免疫反应的理解在很大程度上仍是未知的。我们试图深入了解癌症和癌症伴化疗诱导的恶病质的免疫学基础。用 10 个 C26 细胞给 CD2F1 小鼠接种,然后给予五剂 5-氟尿嘧啶(5FU;30mg/kgLM,ip)或 PBS。使用高参数流式细胞术检查恶病质和肿瘤(TUM)、骨骼肌(SKM)和脂肪组织(AT)免疫细胞群的指标。尽管 5FU 能够阻止肿瘤生长,但 C26 和 C26+5FU 之间的体重百分比下降和肌肉质量没有差异。C26 在 SKM 和 AT 中增加了 CD11bLy6g 和 CD11bLy6c 炎症性髓样细胞;然而,这两种细胞群在 C26+5FU 中都减少了。tSNE 分析显示了 24 个 SKM 巨噬细胞亚群,其中 8 个亚群受到 C26 或 C26+5FU 的改变。C26+5FU 增加了 SKM CD11bCD11c 树突状细胞、CD11bNK1.1 NK 细胞和 CD11bB220 B 细胞,与 C26 相比,减少了 Ly6cCX3CR1CD206CD163CD11cMHCII 浸润的巨噬细胞和其他 CD11bLy6c 髓样细胞。C26 和 C26+5FU 都有升高的 CD11bF480CD206MHCII 或更具体地说 Ly6cCX3CR1CD206CD163CD11cMHCII 促纤维化巨噬细胞。5FU 抑制肿瘤生长,减少 SKM 和 AT 炎症性免疫细胞,但不能预防恶病质,这表明这些细胞不是消耗所必需的。然而,促纤维化细胞和肌肉炎症/萎缩信号似乎与癌症和癌症伴化疗引起的消耗一致,仍然是潜在的治疗靶点。尽管是一种免疫驱动的情况,但我们对恶病质骨骼肌和脂肪组织免疫细胞的理解仍然有限。在这里,我们在有/没有 5-氟尿嘧啶(5FU)的 C26 荷瘤小鼠中鉴定了肿瘤、骨骼肌和脂肪组织中的免疫细胞群。C26 和 C26+5FU 增加了骨骼肌促纤维化巨噬细胞,但 5FU 减少了炎症性髓样细胞,而没有保留质量。肿瘤的存在和化疗对某些免疫细胞有相反的影响,这些免疫细胞似乎不是消耗所必需的。